Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
DoD Tick-Borne Disease Idea Award
The FY16 TBDRP Idea Award promotes new ideas that represent innovative approaches to Lyme disease and other tick-borne disease research and have the potential to make an important contribution to the TBDRP mission.
This award funds conceptually innovative, high-risk/ potentially high-reward research
in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses.
Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.
The following are important aspects of the FY16 TBDRP Idea Award:
• Innovation:
Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to Lyme disease and other tick-borne disease research.
Research that is merely an incremental advance (the next logical step) is not considered innovative.
• Preliminary Data:
Due to this award’s emphasis on innovation, unpublished data from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from the published literature that are relevant to Lyme disease and other tick-borne diseases and support the proposed research project are encouraged, but not required.
• New Investigators:
The FY16 TBDRP Idea Award mechanism encourages applications from investigators in the early stages of their careers.
The New Investigator category of this award mechanism is designed to allow applicants still early in their faculty appointments, or in the process of developing independent research careers, to also compete for funding and bring new, innovative ideas to Lyme disease and other tick-borne disease research.
Applications from New Investigators and Established Investigators will be grouped separately for peer and programmatic reviews, with personnel evaluated by distinct peer review criteria dependent on the category designated.
PIs applying under the New Investigator category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in Lyme disease and other tick-borne disease research and/or possessing other relevant expertise as demonstrated by a record of funding and publications.
It is the responsibility of the PI to describe how the collaboration(s) will augment his or her expertise to best address the research question.
All New Investigator applicants must meet specific eligibility criteria as described in Section I.D., Eligibility Information.
Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this Program Announcement/Funding Opportunity.
A clinical trial is defined as a prospective accrual of patients in which an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy.
This outcome represents a direct effect on the subject of that intervention or interaction.
For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm.
This award funds conceptually innovative, high-risk/ potentially high-reward research
in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses.
Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.
The following are important aspects of the FY16 TBDRP Idea Award:
• Innovation:
Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to Lyme disease and other tick-borne disease research.
Research that is merely an incremental advance (the next logical step) is not considered innovative.
• Preliminary Data:
Due to this award’s emphasis on innovation, unpublished data from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from the published literature that are relevant to Lyme disease and other tick-borne diseases and support the proposed research project are encouraged, but not required.
• New Investigators:
The FY16 TBDRP Idea Award mechanism encourages applications from investigators in the early stages of their careers.
The New Investigator category of this award mechanism is designed to allow applicants still early in their faculty appointments, or in the process of developing independent research careers, to also compete for funding and bring new, innovative ideas to Lyme disease and other tick-borne disease research.
Applications from New Investigators and Established Investigators will be grouped separately for peer and programmatic reviews, with personnel evaluated by distinct peer review criteria dependent on the category designated.
PIs applying under the New Investigator category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in Lyme disease and other tick-borne disease research and/or possessing other relevant expertise as demonstrated by a record of funding and publications.
It is the responsibility of the PI to describe how the collaboration(s) will augment his or her expertise to best address the research question.
All New Investigator applicants must meet specific eligibility criteria as described in Section I.D., Eligibility Information.
Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this Program Announcement/Funding Opportunity.
A clinical trial is defined as a prospective accrual of patients in which an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy.
This outcome represents a direct effect on the subject of that intervention or interaction.
For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm.
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
Not Available
Additional Information of Eligibility:
Not Available
Full Opportunity Web Address:
Contact:
CDMRP Help Desk301-682-5507
Agency Email Description:
CDMRP Help Desk
Agency Email:
help@eBRAP.org
Date Posted:
2016-06-15
Application Due Date:
2016-11-16
Archive Date:
2016-12-16
Social Entrepreneurship
Spotlight
Building a Million Dollar Company Where Everyone Counts
Ganesh Natarajan is the Founder and Chairman of 5FWorld, a new platform for funding and developing start-ups, social enterprises and the skills eco-system in India. In the past two decades, he has built two of India’s high-growth software services companies – Aptech and Zensar – almost from scratch to global success.
Learn How to Identify and Avoid Grant Scams
